Efficacy and safety of MECT plus SSRI in the treatment of refractory depression：a Meta analysis

Abstract:

Objective：To access the efficacy and safety of MECT plus SSRI in the treatment of refractory depression. Methods：Random－ized controlled trials（RCTs） in relevant databases：Cochrane Library，Pubmed，Web of Knowledge，Ebsco，Chinese Biomedical Litera－ture，China National Knowledge Internet，Wanfang Data and VIP from 1900 to April 2013 were searched. Quality of the literature in－cluded was evaluated and data was extracted. Review Manager 5.0 software was used for Meta analysis. Results：Seven RCTs of 461 patients were included in our study，230 patients in MECT plus SSRI group and 231 patients in SSRI group. Meta analysis results indicated that effective rate and curative rate of MECT plus SSRI group are better than those of SSRI group，with statistically differences（curative rate：Z=4.52，P=0.000；effective rate：Z=7.71，P=0.000）. In addition，incidence of recent memory disorders in MECT plus SSRI group was higher than that of SSRI group（P=0.013）. There was no difference in the rest of side effects between two groups（P >0.05）. Conclusion：MECT plus SSRI is an effective and safety method in the treatment of refractory depression.